Lion Roars on Long-Term Metastatic Melanoma Data
By Marie Powers
Monday, September 30, 2013
Little Lion Biotechnologies Inc., the surviving entity of a merger earlier this year with Genesis Biopharma Inc., reported promising long-term findings from a Phase II trial in Stage IV metastatic melanoma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.